Transcriptomics

Dataset Information

0

Dissecting the mechanisms underlying the Cytokine Release Syndrome (CRS) mediated by T Cell Bispecific Antibodies

ABSTRACT: This SuperSeries is composed of the SubSeries listed below.

ORGANISM(S): Homo sapiens

PROVIDER: GSE234676 | GEO | 2023/06/17

REPOSITORIES: GEO

Json Xml

Similar Datasets

Transcriptomics Dissecting the mechanisms underlying the Cytokine Release Syndrome (CRS) mediated by T Cell Bispecific Antibodies
2023-06-17 | GSE234673 | GEO
Transcriptomics Dissecting the mechanisms underlying the Cytokine Release Syndrome (CRS) mediated by T Cell Bispecific Antibodies
2023-06-17 | GSE234668 | GEO
Unknown Tocilizumab: The Key to Stop Coronavirus Disease 2019 (COVID-19)-Induced Cytokine Release Syndrome (CRS)?
| S-EPMC7649275 | biostudies-literature
Unknown Efficient tumor killing and minimal cytokine release with novel T-cell agonist bispecific antibodies.
| S-EPMC6601548 | biostudies-literature
Unknown Potent ex vivo armed T cells using recombinant bispecific antibodies for adoptive immunotherapy with reduced cytokine release.
| S-EPMC8126293 | biostudies-literature
Unknown Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?
| S-EPMC7151347 | biostudies-literature
Unknown Generation of T-cell-redirecting bispecific antibodies with differentiated profiles of cytokine release and biodistribution by CD3 affinity tuning.
| S-EPMC8277787 | biostudies-literature
Unknown Dissecting the molecular basis of high viscosity of monospecific and bispecific IgG antibodies.
| S-EPMC6927759 | biostudies-literature
Unknown Tumor Microenvironment Composition and Severe Cytokine Release Syndrome (CRS) Influence Toxicity in Patients with Large B-Cell Lymphoma Treated with Axicabtagene Ciloleucel.
| S-EPMC7501265 | biostudies-literature
Unknown Rituximab and cytokine release syndrome.
| S-EPMC3364040 | biostudies-literature